Atlas Trials

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

Clinical trial NCT06340581 · WITHDRAWN

Trial details

NCT number
NCT06340581
Sponsor
AstraZeneca
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2024-10-17
Primary completion
2025-02-27
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.